{
  "id": 3948611,
  "title": "XORTX Announces Termination and Postponement of Investor Relations Program",
  "url": "https://urgent.news/2026/08/28/xortx-announces-termination-and-postponement-of-investor-relations",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-28T11:02:01.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xortx-announces-termination-and-postponement-of-investor-relations-program"
  },
  "original_language": "en",
  "account": null,
  "summary": "CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}